In reply to letter to editor regarding ``a multicenter, randomised, double-blind, imipenem/cilastatin-controlled clinical study of cefiderocol for the treatment of complicated urinary tract infections caused by Gram-negative pathogens in Chinese adults''
In reply to letter to editor regarding ``a multicenter, randomised, double-blind, imipenem/cilastatin-controlled clinical study of cefiderocol for the treatment of complicated urinary tract infections caused by Gram-negative pathogens in Chinese adults''. // International Journal of Antimicrobial Agents. – URL: https://www.sciencedirect.com/science/article/pii/S0924857926002700?dgcid=rss_sd_all
In reply to letter to editor regarding ``a multicenter, randomised, double-blind, imipenem/cilastatin-controlled clinical study of cefiderocol for the treatment of complicated urinary tract infections caused by Gram-negative pathogens in Chinese adults''. International Journal of Antimicrobial Agents. https://www.sciencedirect.com/science/article/pii/S0924857926002700?dgcid=rss_sd_all
“In reply to letter to editor regarding ``a multicenter, randomised, double-blind, imipenem/cilastatin-controlled clinical study of cefiderocol for the treatment of complicated urinary tract infections caused by Gram-negative pathogens in Chinese adults''.” International Journal of Antimicrobial Agents.
@article{article49323,
title = {In reply to letter to editor regarding ``a multicenter, randomised, double-blind, imipenem/cilastatin-controlled clinical study of cefiderocol for the treatment of complicated urinary tract infections caused by Gram-negative pathogens in Chinese adults''},
journal = {International Journal of Antimicrobial Agents},
url = {https://www.sciencedirect.com/science/article/pii/S0924857926002700?dgcid=rss_sd_all}
}